EA201290170A2 - Добавляемые в активное вещество однородные, жесткие сферические нанопористые частицы фосфата кальция и способы их производства и использования - Google Patents

Добавляемые в активное вещество однородные, жесткие сферические нанопористые частицы фосфата кальция и способы их производства и использования

Info

Publication number
EA201290170A2
EA201290170A2 EA201290170A EA201290170A EA201290170A2 EA 201290170 A2 EA201290170 A2 EA 201290170A2 EA 201290170 A EA201290170 A EA 201290170A EA 201290170 A EA201290170 A EA 201290170A EA 201290170 A2 EA201290170 A2 EA 201290170A2
Authority
EA
Eurasian Patent Office
Prior art keywords
particles
active substance
compositions
added
active matter
Prior art date
Application number
EA201290170A
Other languages
English (en)
Other versions
EA027992B1 (ru
EA201290170A3 (ru
Inventor
Тецуро Огава
Акира Ямамото
Original Assignee
Лаборэтори Скин Кэа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборэтори Скин Кэа, Инк. filed Critical Лаборэтори Скин Кэа, Инк.
Publication of EA201290170A2 publication Critical patent/EA201290170A2/ru
Publication of EA201290170A3 publication Critical patent/EA201290170A3/ru
Publication of EA027992B1 publication Critical patent/EA027992B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0279—Porous; Hollow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Рассматриваются однородные, жесткие сферические нанопористые частицы фосфата кальция, определяющие внутреннее пространство и количество активного вещества, присутствующего во внутреннем пространстве. Также рассматриваются композиции для топической доставки, включающие частицы, добавляемые в активное вещество, а также способы производства частиц и топических композиций. Частицы и композиции используются в ряде различных применений, включая доставку активного вещества.
EA201290170A 2008-09-23 2009-09-23 Способ получения однородных, жестких, сферических, нанопористых частиц фосфата кальция, содержащих активное вещество EA027992B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9950008P 2008-09-23 2008-09-23
PCT/US2009/058108 WO2010039560A2 (en) 2008-09-23 2009-09-23 Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same

Publications (3)

Publication Number Publication Date
EA201290170A2 true EA201290170A2 (ru) 2012-11-30
EA201290170A3 EA201290170A3 (ru) 2013-03-29
EA027992B1 EA027992B1 (ru) 2017-09-29

Family

ID=42074119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290170A EA027992B1 (ru) 2008-09-23 2009-09-23 Способ получения однородных, жестких, сферических, нанопористых частиц фосфата кальция, содержащих активное вещество

Country Status (17)

Country Link
US (5) US8535723B2 (ru)
EP (1) EP2480210A4 (ru)
JP (1) JP5730316B2 (ru)
KR (4) KR20160083953A (ru)
CN (1) CN102802610A (ru)
AU (1) AU2009298814B2 (ru)
BR (1) BR112012006635B8 (ru)
CA (1) CA2778604C (ru)
CL (1) CL2012000726A1 (ru)
EA (1) EA027992B1 (ru)
IL (2) IL218808A (ru)
MX (1) MX356209B (ru)
MY (1) MY162982A (ru)
NZ (1) NZ599544A (ru)
SG (2) SG10201903125QA (ru)
WO (1) WO2010039560A2 (ru)
ZA (1) ZA201202948B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480210A4 (en) * 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
PL2413902T3 (pl) * 2009-03-18 2020-01-31 Incarda Therapeutics, Inc. Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
ES2942923T3 (es) * 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
KR20120056824A (ko) * 2009-08-19 2012-06-04 바이엘 파마 악티엔게젤샤프트 소아과 용도를 위한 약물 전달 시스템 （웨이퍼）
CN102905675B (zh) * 2009-11-10 2018-11-16 护肤品实验室有限公司 包含均匀、硬质、球形、纳米多孔磷酸钙颗粒的防晒剂组合物及其制备和使用方法
EP2665483B1 (en) * 2011-01-19 2020-08-26 Laboratory Skin Care, Inc. Topical minocycline compositions and methods of using the same
CN107875391A (zh) * 2011-08-16 2018-04-06 实验室护肤股份有限公司 细干颗粒腺苷组合物和包括其的局部制剂
CN102552913B (zh) * 2012-01-19 2013-06-19 中国科学院上海硅酸盐研究所 一种纳米结构磷酸钙双载药体系及其制备方法
CN103284929B (zh) * 2012-02-23 2015-08-12 黄曦 一种护肤品及其制备方法
US11844852B2 (en) * 2012-02-23 2023-12-19 Fe:I Beauty Tech, Inc. Skincare product and method of preparation thereof
CN102579355B (zh) * 2012-03-19 2013-03-06 天津大学 米托蒽醌纳米磷酸氢钙制剂及其制备方法
CZ2012724A3 (cs) * 2012-10-24 2014-07-23 Agra Group, A.S. Mezoporézní částice, jejich použití a přípravek je obsahující
NZ713342A (en) * 2013-03-15 2020-12-18 Laboratory Skin Care Inc Fine dry particulate retinoid active agent compositions and topical formulations including the same
MY175420A (en) 2013-03-15 2020-06-24 Laboratory Skin Care Inc Fine dry particulate resveratrol active agent compositions and topical formulations including the same
CN104856889B (zh) * 2014-09-22 2017-05-10 北京大学口腔医学院 缓释氯己定无定形磷酸钙纳米颗粒的制备方法
CN105336873B (zh) * 2015-11-05 2018-12-07 广州竞择微电子技术有限公司 一种柔性光电子器件用基板及其制备方法
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常
CA3026041A1 (en) * 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2018134783A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP6961504B2 (ja) * 2018-01-26 2021-11-05 国立大学法人 岡山大学 徐放性デバイス
EP3768378A4 (en) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE
KR102221493B1 (ko) * 2018-12-12 2021-02-26 성균관대학교산학협력단 핵산 기반의 칼슘 포스페이트 나노 소재를 합성하는 방법 및 이에 의해 합성된 핵산 기반의 칼슘 포스페이트 나노 소재
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN113054121B (zh) * 2019-12-28 2022-07-05 Tcl科技集团股份有限公司 纳米材料及其制备方法、半导体器件

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5158756A (en) 1989-06-24 1992-10-27 Asahi Kogaku Kogyo Kabushiki Kaisha Porous particles of calcium phosphate compound and production process thereof
JPH07330319A (ja) * 1994-06-03 1995-12-19 Asahi Optical Co Ltd 皮膚清浄用粉末組成物
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US6096324A (en) * 1995-06-13 2000-08-01 Laboratory Skin Care Methods of delivering materials into the skin, and compositions used therein
US6579516B1 (en) * 1995-06-13 2003-06-17 Zahra Mansouri Methods of delivering materials into the skin, and compositions used therein
US6416774B1 (en) * 1996-05-09 2002-07-09 The Trustees Of The University Of Pennsyvania Hollow bone mineral-like calcium phosphate particles
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
JP2004075662A (ja) * 2002-06-20 2004-03-11 Mukku:Kk 徐放性組成物、その製造方法およびその製剤
WO2004112751A1 (ja) 2003-06-18 2004-12-29 Ltt Bio-Pharma Co., Ltd. 薬物含有徐放性微粒子、その製造法、及びそれを含有する製剤
FR2856594B1 (fr) * 2003-06-26 2006-03-03 Oreal Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s)
US20050031559A1 (en) 2003-07-07 2005-02-10 L'oreal Cosmetic composition for caring for and/or making up skin
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
BRPI0507680A (pt) 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
EP1737378A2 (en) * 2004-04-02 2007-01-03 Baylor College of Medicine Novel modification of medical prostheses
US20060073205A1 (en) * 2004-10-04 2006-04-06 Kotoe Ohta Controlled release granules comprising porous silica core
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
CN1813657A (zh) * 2005-12-15 2006-08-09 孙振淋 纳米磷酸钙类盐在化妆产品中的应用方法
CN100509695C (zh) * 2006-02-21 2009-07-08 西南交通大学 多孔羟基磷灰石和磷酸钙陶瓷的制备方法
FR2898807B1 (fr) * 2006-03-23 2008-12-05 Oreal Composition comprenant de l'hydroxyapatite et un sel de calcium pour renforcer la fonction barriere de la peau et/ou des semi-muqueuses
CN100460016C (zh) * 2006-04-21 2009-02-11 华南理工大学 介孔磷酸钙纳米颗粒及其制备方法和应用
EP2480210A4 (en) * 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
ES2942923T3 (es) * 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
NZ713342A (en) * 2013-03-15 2020-12-18 Laboratory Skin Care Inc Fine dry particulate retinoid active agent compositions and topical formulations including the same

Also Published As

Publication number Publication date
MY162982A (en) 2017-07-31
US8535723B2 (en) 2013-09-17
CL2012000726A1 (es) 2013-01-11
CA2778604C (en) 2021-10-05
EP2480210A2 (en) 2012-08-01
KR20160083953A (ko) 2016-07-12
IL218808A (en) 2017-10-31
IL218808A0 (en) 2012-06-28
AU2009298814B2 (en) 2016-05-05
US10028903B2 (en) 2018-07-24
WO2010039560A2 (en) 2010-04-08
BR112012006635B1 (pt) 2021-04-06
BR112012006635A2 (pt) 2016-05-03
KR20180089553A (ko) 2018-08-08
EP2480210A4 (en) 2016-07-13
US20210015739A1 (en) 2021-01-21
SG10201903125QA (en) 2019-05-30
AU2009298814A1 (en) 2012-06-21
US20190117558A1 (en) 2019-04-25
SG10201406431QA (en) 2014-11-27
KR101689635B1 (ko) 2016-12-26
MX2012003542A (es) 2012-09-07
WO2010039560A3 (en) 2015-05-21
IL255112A0 (en) 2017-12-31
ZA201202948B (en) 2014-08-27
BR112012006635B8 (pt) 2021-05-25
EA027992B1 (ru) 2017-09-29
IL255112B (en) 2019-09-26
US20240082147A1 (en) 2024-03-14
EA201290170A3 (ru) 2013-03-29
US20140199400A1 (en) 2014-07-17
NZ599544A (en) 2014-04-30
US10758478B2 (en) 2020-09-01
KR20120104188A (ko) 2012-09-20
CN102802610A (zh) 2012-11-28
MX356209B (es) 2018-05-18
CA2778604A1 (en) 2010-04-08
JP5730316B2 (ja) 2015-06-10
KR20170096241A (ko) 2017-08-23
JP2013505293A (ja) 2013-02-14
US20100086606A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
EA201290170A2 (ru) Добавляемые в активное вещество однородные, жесткие сферические нанопористые частицы фосфата кальция и способы их производства и использования
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
EA201391030A1 (ru) Композиции моноциклина для местного применения и способы их применения
EA201200939A1 (ru) Липиды, липидные композиции и способы их применения
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201171286A1 (ru) Новая технология изготовления индометацина
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201390184A1 (ru) Активирующие амрк гетероциклические соединения и способы их использования
EA201171285A1 (ru) Новая технология изготовления диклофенака
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
TR200806298A2 (tr) Farmasötik formülasyon
EA201390799A1 (ru) Триазолопиридины
MX2010004389A (es) Formulaciones de vancomicina liposomales.
EA201171284A1 (ru) Новая технология изготовления напроксена
EA201300337A1 (ru) Композиция, содержащая пирипиропеновый инсектицид и основание
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
BR112013011845B8 (pt) enxaguatório bucal compreendendo aminoácido básico e conservante e uso cosmético do enxaguatório bucal
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA201201170A1 (ru) Гетариламинонафтиридины
EA201001569A1 (ru) Инкапсуляция биологически активных агентов
EA201591618A1 (ru) Замещенные имидазопиридазины
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
EA201391555A1 (ru) Составы суспензионного типа для местного применения, содержащие циклический депсипептид
EA201390467A1 (ru) Композиции антител и способы применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU